Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of intravenous
weekly paclitaxel given with intravenous carboplatin and bevacizumab in patients with
epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that are to receive
neoadjuvant chemotherapy (prior to surgical cytoreduction). Patients will then undergo
surgery which will allow an objective measure of response to the above regimen as well as
assessment of surgical outcomes.